These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 32983101)

  • 1. Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Innate Lymphoid Cell Subtype Equilibrium.
    Creyns B; Jacobs I; Verstockt B; Cremer J; Ballet V; Vandecasteele R; Vanuytsel T; Ferrante M; Vermeire S; Van Assche G; Ceuppens JL; Breynaert C
    Front Immunol; 2020; 11():1847. PubMed ID: 32983101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Alterations in the Composition of Mucosal Innate Lymphoid Cells in Newly Diagnosed and Established Crohn's Disease and Ulcerative Colitis.
    Forkel M; van Tol S; Höög C; Michaëlsson J; Almer S; Mjösberg J
    J Crohns Colitis; 2019 Jan; 13(1):67-78. PubMed ID: 30496425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ILC3 function as a double-edged sword in inflammatory bowel diseases.
    Zeng B; Shi S; Ashworth G; Dong C; Liu J; Xing F
    Cell Death Dis; 2019 Apr; 10(4):315. PubMed ID: 30962426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate Lymphoid Cells in Intestinal Homeostasis and Inflammatory Bowel Disease.
    Saez A; Gomez-Bris R; Herrero-Fernandez B; Mingorance C; Rius C; Gonzalez-Granado JM
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crohn's Disease Is Associated With Activation of Circulating Innate Lymphoid Cells.
    Mazzurana L; Bonfiglio F; Forkel M; D'Amato M; Halfvarson J; Mjösberg J
    Inflamm Bowel Dis; 2021 Jun; 27(7):1128-1138. PubMed ID: 33295628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innate lymphoid cells in homeostasis, infection, chronic inflammation and tumors of the gastrointestinal tract.
    Fuchs A; Colonna M
    Curr Opin Gastroenterol; 2013 Nov; 29(6):581-7. PubMed ID: 24100718
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Tang Y; Tan SA; Iqbal A; Li J; Glover SC
    J Immunol Res; 2019; 2019():9406146. PubMed ID: 31321245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis.
    Villanova F; Flutter B; Tosi I; Grys K; Sreeneebus H; Perera GK; Chapman A; Smith CH; Di Meglio P; Nestle FO
    J Invest Dermatol; 2014 Apr; 134(4):984-991. PubMed ID: 24352038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis.
    Ciccia F; Guggino G; Rizzo A; Saieva L; Peralta S; Giardina A; Cannizzaro A; Sireci G; De Leo G; Alessandro R; Triolo G
    Ann Rheum Dis; 2015 Sep; 74(9):1739-47. PubMed ID: 25902790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis.
    Overstreet AM; LaTorre DL; Abernathy-Close L; Murphy SF; Rhee L; Boger AM; Adlaka KR; Iverson AM; Bakke DS; Weber CR; Boone DL
    Mucosal Immunol; 2018 Sep; 11(5):1454-1465. PubMed ID: 29988117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
    Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
    Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation.
    Powell N; Lo JW; Biancheri P; Vossenkämper A; Pantazi E; Walker AW; Stolarczyk E; Ammoscato F; Goldberg R; Scott P; Canavan JB; Perucha E; Garrido-Mesa N; Irving PM; Sanderson JD; Hayee B; Howard JK; Parkhill J; MacDonald TT; Lord GM
    Gastroenterology; 2015 Aug; 149(2):456-67.e15. PubMed ID: 25917784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
    Pedersen G
    Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced CD27
    Pararasa C; Zhang N; Tull TJ; Chong MHA; Siu JHY; Guesdon W; Chavele KM; Sanderson JD; Langmead L; Kok K; Spencer J; Vossenkamper A
    Front Immunol; 2019; 10():361. PubMed ID: 30891036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
    Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
    Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wogonin improves colitis by activating the AhR pathway to regulate the plasticity of ILC3/ILC1.
    Ye Q; Huang S; Wang Y; Chen S; Yang H; Tan W; Wu Z; Wang A; Chen Y
    Phytomedicine; 2024 Jun; 128():155425. PubMed ID: 38518634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulation of Group 3 Innate Lymphoid Cells in the Pathogenesis of Inflammatory Bowel Disease.
    Forkel M; Mjösberg J
    Curr Allergy Asthma Rep; 2016 Oct; 16(10):73. PubMed ID: 27645534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod Alters Tissue Distribution and Cytokine Production of Human and Murine Innate Lymphoid Cells.
    Eken A; Yetkin MF; Vural A; Okus FZ; Erdem S; Azizoglu ZB; Haliloglu Y; Cakir M; Turkoglu EM; Kilic O; Kara I; Dönmez Altuntaş H; Oukka M; Kutuk MS; Mirza M; Canatan H
    Front Immunol; 2019; 10():217. PubMed ID: 30828332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Barré A; Colombel JF; Ungaro R
    Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.
    Ribaldone DG; Pellicano R; Vernero M; Caviglia GP; Saracco GM; Morino M; Astegiano M
    Scand J Gastroenterol; 2019 Apr; 54(4):407-413. PubMed ID: 30945576
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.